Toulouse, France
Toulouse, France

Paul Sabatier University is a French university, in the Academy of Toulouse.Founded in 1229, the University of Toulouse is one of the oldest in Europe. Today’s Toulouse III was named for Paul Sabatier, winner of the 1912 Nobel prize in chemistry, when it was established on the foundations of the old university in 1969. The Université Paul Sabatier , an educational leader in France’s Midi-Pyrénées region, offers a broad array of programs in the science, technology, health, and athletics. Wikipedia.


Time filter

Source Type

Patent
French National Center for Scientific Research and University Paul Sabatier | Date: 2015-04-13

A process for preparing phyllomineral synthetic particles formed from constituent chemical elements in stoichiometric proportions including at least one chemical element selected from the group formed from silicon and germanium, and at least one chemical element selected from the group formed from divalent metals and trivalent metals, by a continuous solvothermal treatment at a pressure above 1 MPa and at a temperature between 100 C. and 600 C., by making the reaction medium circulate continuously in a solvothermal treatment zone of a continuous reactor (15) with a residence time of the reaction medium in the solvothermal treatment zone that is suitable for continuously obtaining, at the outlet of the solvothermal treatment zone, a suspension including the phyllomineral synthetic particles.


The invention relates to a compound for use for inducing apoptosis in a cancerous cell, wherein said compound is selected from the group consisting of ApoO, a variant or a fragment thereof, their mixtures, and a vector encoding for said ApoO, variant or fragment thereof. The invention further relates to a compound for use for treating a pathophysiological situation, wherein said compound is an inhibitor of the ApoO activity or of the ApoO gene expression.


Patent
University Paul Sabatier, French National Center for Scientific Research, Toulouse 1 University Capitole, French Institute of Health and Medical Research | Date: 2015-06-16

The invention concerns an inhibitor of the expression of chemokine CCL7 or an inhibitor of the expression of the receptor CCR3 or an inhibitor of CCL7/CCR3 interaction for the use of same to prevent or treat the extension of prostate cancer outside the prostatic capsule in a subject. The invention also concerns a method for determining the degree of aggressiveness of a prostate cancer tumour in a subject suffering from prostate cancer, comprising a step of determining the concentration or level of expression of the receptor CCR3 in a sample of prostate tumour cells obtained from said subject.


Patent
University Paul Sabatier and French National Center for Scientific Research | Date: 2015-03-27

Providing Nuclear factor (erythroid-derived 2)-like 2 (NRF2)-activated genes products, e.g. SOD1 and CAT, in their use in the prognosis of an OPA1 gene- or OPA1 gene product-deficit-induced disease, or related complications, e.g. optic atrophy and optic neuropathy, in a biological sample selected from fibroblasts, epithelial cells, blood samples or a mixture thereof, of a patient affected or suspected to be affected by the disease.


Patent
Vaiomer, University Paul Sabatier and French National Center for Scientific Research | Date: 2015-05-15

The present invention relates to a method for identifying a relationship between biological elements, said elements optionally having a measurable activity, the method comprising the following steps:


Patent
French National Center for Scientific Research and University Paul Sabatier | Date: 2015-07-20

The invention relates to a process for preparing an electrically conductive composite film, in particular in the form of a self-supported film or of a prepreg, comprising at least one thermoplastic polymer resin and electrically conductive particles chosen from a) graphene, carbon nanotubes, carbon nanofibres, and mixtures thereof; and b) filiform metal nanoparticles; to a process for preparing an electrically conductive laminated composite structure comprising such an electrically conductive composite film; to said electrically conductive composite film, to said electrically conductive laminated composite structure, and also to the uses thereof.


Patent
University Paul Sabatier and French National Center for Scientific Research | Date: 2017-02-01

The present invention provides the use of the activity or expression level of Nuclear factor (erythroid -derived 2)-like 2 (NRF2)-activated genes products, e.g. SOD1 and CAT, in the prognosis of an OPA1 gene- or OPA1 gene product- deficit-induced disease, e.g. optic atrophy and optic neuropathy, or related complications by detecting expression or activity in a biological sample selected from fibroblasts, epithelial cells, blood samples or a mixture thereof, of a patient affected or suspected to be affected by said disease.


Grant
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: INFRADEV-02-2016 | Award Amount: 9.05M | Year: 2017

The European Solar Telescope (EST) will be a revolutionary Research Infrastructure that will play a major role in answering key questions in modern Solar Physics. This 4-meter class solar telescope, to be located in the Canary Islands, will provide solar physicists with the most advanced state-of-the-art observing tools to transform our understanding of the complex phenomena that drive the solar magnetic activity. The principal objective of the present Preparatory Phase is to provide both the EST international consortium and the funding agencies with a detailed plan regarding the implementation of EST. The specific objectives of the proposed preparatory phase are: (1) to explore possible legal frameworks and related governance schemes that can be used by agencies to jointly establish, construct and operate EST as a new research infrastructure, with the implementation of an intermediate temporary organisational structure, as a previous step for future phases of the project; (2) to explore funding schemes and funding sources for EST, including a proposal of financial models to make possible the combination of direct financial and in-kind contributions towards the construction and operation of EST; (3) to compare the two possible sites for EST in the Canary Islands Astronomical Observatories and prepare final site agreements; (4) to engage funding agencies and policy makers for a long-term commitment which guarantees the construction and operation phases of the Telescope; (5) to involve industry in the design of EST key elements to the required level of definition and validation for their final production; (6) to enhance and intensify outreach activities and strategic links with national agencies and the user communities of EST. To accomplish the aforementioned goals, this 4-year project, promoted by the European Association for Solar Telescopes (EAST) and the PRE-EST consortium, encompassing 23 research institutions from 16 countries, will set up the Project Office


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-24-2015 | Award Amount: 14.94M | Year: 2016

Pharmacogenomics is the study of genetic variability affecting an individuals response to a drug. Its use allows personalized medicine and reduction in trial and error prescribing leading to more efficacious, safer and cost-effective drug therapy. The U-PGx consortium will investigate a pre-emptive genotyping approach (that is: multiple pharmacogenomic variants are collected prospectively and embedded into the patients electronic record) of a panel of important pharmacogenomic variants as a new model of personalised medicine. To meet this goal we combine existing pharmacogenomics guidelines and novel health IT solutions. Implementation will be conducted at a large scale in seven existing European health care environments and accounts for the diversity in health system organisations and settings. Feasibility, health outcome and cost-effectiveness will be investigated. We will formulate European strategies for improving clinical implementation of pharmacogenomics based on the findings of this project.


Grant
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2016 | Award Amount: 4.00M | Year: 2017

Lightning is an extremely energetic electric discharge process in our atmosphere. It significantly affects the concentration of greenhouse gases and it threatens electrical and electronic devices, in particular, when placed on elevated structures like wind turbines or aircraft, and when these structures are built with modern composite materials with inherently low electric conductivity. In addition, even our fundamental understanding of atmospheric electricity is far from complete. New discharge processes in the atmosphere above thunderstorms have been discovered, the so-called Transient Luminous Events (TLEs) in the stratosphere and mesosphere, and Terrestrial Gamma-ray Flashes (TGFs) that emit particle beams of antimatter. These phenomena demand thorough investigations, in geophysics and in the related fields of plasma and high-voltage technology where similar discharges appear. These challenges are approached within the SAINT project with a multidisciplinary and inter-sectorial training platform for 15 ESRs. The platform brings together satellite and ground observations with modelling and lab experiments. It couples scientific studies to applications relevant to industries developing satellite data products, plasma discharge technologies, lightning detection systems and lightning protection devices. With SAINT, we take advantage of the extraordinary opportunity presented by three simultaneous space missions with dedicated instruments to study lightning discharges, TLEs and TGFs, to integrate the unique space data with dedicated novel ground observations, model developments and lab experiments. SAINT will train the next generation of young, innovative scientists to shape the future of research and technology in Europe.

Loading University Paul Sabatier collaborators
Loading University Paul Sabatier collaborators